Objective: Guidelines recommend 3-year cervical cancer screening intervals to avoid unnecessary invasive procedures; however, regular testing remains critical. We evaluated trends in cervical cancer screening among low-income women receiving family planning-related services and their association with patient and provider characteristics.
C ervical cancer screening decreases cervical cancer mortality 1 ; however, not all populations have equally benefited. Disproportionately low rates of cervical cytology testing and elevated cancer incidence and mortality have been documented among minority, immigrant, and uninsured women. [2] [3] [4] [5] [6] In 2013, Latinas had the highest incidence rates of cervical cancer (9.4 per 100,000 vs 8.9 per 100,000 for African Americans and 7.5 per 100,000 for nonLatino whites), and African American and Latina women had the highest cervical cancer mortality rates (3.9 per 100,000 and 2.6 per 100,000, respectively, vs 2.1 per 100,000 for non-Latino whites). 6 For decades, cervical cancer screening guidelines recommended annual screening. However, cervical cytology has a relatively low sensitivity, resulting in needless invasive procedures for many women that have been associated with premature delivery and emotional distress. 7, 8 As a result, by 2012, US Preventive Services Task Force and the American Cancer Society in collaboration with American Society for Colposcopy and Cervical Pathology and American Society for Clinical Pathology independently issued revised guidelines-both recommending screening to start at 21 years and end at 65 years of age and intervals every 3 years when using cytology alone and specifically advised against annual screenings. [9] [10] [11] [12] Healthy people set as an objective that by 2020, 93% of females aged 21 to 65 years should receive cervical cancer screening based on the most recent guidelines. 13 Nationwide, the percentage of women aged 21 to 65 years who had a cervical cancer screening test in the past 3 years showed a small decline from 81% in 2010 to 79% in 2015.
14 This trend may have been impacted by changes in access to women's health services, confusion in changing guidelines, or difficulty in remembering screening due dates.
In this analysis, we used California's Family Planning, Access, Care, and Treatment (Family PACT) program claims and program enrollment data to examine trends in and correlates of guideline adherent cervical cancer screening among women who used publicly funded family planning services. 15 In 2013, the Family PACT program disseminated the information to its provider base of more than 2,200 sites in California. 16 We also hypothesized that the replacement of pelvic examination chlamydia screening with urine or self-swab potentially discouraged clinicians to conduct a speculum examination for the cervical cytology screening. In this case, urine-based annual chlamydia testing for women aged 21 to 24 years would not show a similar decrease over the years. We therefore assessed trends in rates of guideline-supported chlamydia screening practices for women aged 21 to 24 years during the analysis period to identify potential missed cervical cancer screening opportunities.
MATERIALS AND METHODS

Study Data and Design
We analyzed Family PACT fee-for-service paid claims and program enrollment data from 2011 to 2015. By design of the program, all women selected were eligible for no-cost family planning-related services for at least 1 year and had been seen by a clinician provider for a family planning-related visit at least once (see Supplement for definitions of provider 
Sample
As part of a comprehensive intervention study, we identified 243 Family PACT enrolled clinic sites located in 10 mostly Southern California counties that had sufficiently large data volume just before the July 2015 intervention start (see Supplement for details on 'sufficient data volume,' http://links.lww.com/LGT/A83). These Family PACT clinic sites were public sector providers such as Federally Qualified Health Centers and county health departments as well as private group and solo medical practices. No Planned Parenthood health centers were included because they have a unique monitoring and tracking system for cervical cancer screening. Of these 243 sites, we excluded 27 sites that served less than 1 female aged 21 to 29 biannually and/or were not enrolled during the entire 2011 to 2015 analysis time frame, resulting in 216 clinic sites (see Figure 1) .
We defined the patient population among the 216 sites as the 661,345 females who had at least 1 family-planning clinician visit between July 1, 2011, and June 30, 2015. We excluded 378 women because they had incomplete demographic information such as date of birth. Data for 121,319 women outside ages 21 to 64 years during each index period were also excluded, resulting in a final sample size of 540,026 women. Women younger than 21 years were not included in the analysis because Family PACT restricted reimbursement for cervical cytology testing for women younger than 21 years in July 2013. Women older than 65 years were also excluded because the guidelines recommend to stop screening at age of 65 years if there is known history of normal cytology.
Cervical Cancer Screening Measures
The main outcome was cervical cytology test claims that were consistent with screening guidelines (see Supplement for details on cervical cytology test claims, http://links.lww.com/ LGT/A83). For each of the eight 6-month visit periods, we calculated rates of 3-and 1-year cervical cancer screening. Because the screening guideline intervals changed during the observation period (i.e., annual screening was recommended in 2011-2012 and triennial screening from 2013-2015), we examined (a) rates consistent with annual screening and (b) rates consistent with triennial screening. The denominator for each measure was the number of women in the selected age group (21-24, 25-29, and 30-64 years) who had at least 1 clinician visit in the 6-month visit period, and the numerator was the number of women who had at least 1 cervical cytology test claimed within the 6-month visit period or 1 year ago (for annual screening) or 3 years ago (for triennial screening). Our look-back period ensures a minimum of 1-year (maximum 18 months) and 3-year (maximum 42 months) cervical cytology test window for every woman, regardless of the timing of her clinician visit(s) within the 6-month visit period.
Our 3-year cervical cancer screening measure is generally comparable with the structure of the National Quality Forumendorsed Healthcare Effectiveness Data and Information Set measure of cervical cancer screening. 17, 18 There are 3 primary differences. First, we used a 6-month measurement period rather than calendar year. Second, our denominator included women actually seen by a clinician in the context of a family planning-related visit when they were at least 21 years old in contrast to solely being eligible for such a visit. Finally, we did not additionally assess human papillomavirus (HPV) co-testing every 5 years for women aged 30 to 64 years. Human papillomavirus co-testing was not a Family PACT-recommended clinical practice for the majority of the study period, and exploratory analyses revealed that including HPV test data in our measure would have resulted in only marginally higher rates of screening for the older age groups. 19 
Chlamydia Screening
We also conducted a subanalysis on annual chlamydia screening among young women to explore whether trends in cervical cancer screening paralleled those in preventive testing. California Sexually Transmitted Disease screening recommendations advise annual testing for chlamydia for women aged 21 to 24 years. 20 We therefore calculated the number of women in this age group who were screened for chlamydia and defined missed opportunity as the number of women who were screened for chlamydia but not cervical cancer. We limited the study observation period from June 2012 to June 2015 because we did not receive chlamydia testing data for 2011. For each 6-month visit period, we calculated rates of chlamydia screening. The denominator was the number of women aged 21 to 24 years who had at least 1 clinician visit in the 6-month visit period, and the numerator was the number of women who had at least 1 chlamydia test within the 6-month visit period or 1 year ago (see Supplement for details on chlamydia test, http://links.lww.com/LGT/A83). Our look-back period ensures a minimum 1-year (maximum 18 months) chlamydia test window for every woman, regardless of the timing of her clinician visit (s) within the 6-month visit period.
Patient and Clinic Characteristics
We obtained patient characteristics, including race/ethnicity, primary language, and age group from Family PACT client enrollment data. A client was defined to a single provider based on her first clinician visit date with 1 of 216 selected sites between July 2011 and June 2015. Age was calculated based on the first day of first 6-month visit period in which she was 21 through 64 years old. Clinic site characteristics county and site type (private vs public) were derived from provider enrollment data. To classify geography type (urban vs rural), we used information from the most current clinical site address and matched it to the Medical Service Study Areas (MSSA) definition. 21 Urban MSSAs were defined as a population range of 75,000 to 125,000 persons, and rural MSSAs had a population density of less than 250 persons per square mile. Clinic site address from most recent enrollment record was also used to capture enrollment in Every Woman Counts, another state program that covers preventive cancer screenings for uninsured low-income women. 22 
Statistical Analyses
We prepared descriptive statistics to describe client and provider characteristics as well as the percentage of women receiving guideline-specific cervical cancer and chlamydia screening by client and provider characteristics. We used logistic regression models to estimate subpopulation-specific trends in 3-year cervical cancer screening over time and to compare trends between subgroups. Each model included a linear time effect (in 6-month increments), a fixed subgroup effect, and a subgroup-by-time interaction term. This method was also used for comparing the decline rate of 3-year cervical cancer screening versus rate of annual chlamydia screening. Trends were estimated using model contrasts and were summarized in terms of odds ratios (ORs) and 95% confidence intervals (CIs). Differences in trends between subgroups were summarized in terms of ORs, 95% CIs, and p values. Statistical significance was defined as a p value of less than .05. All analyses were performed using R Version 3. 
Role of the Funding Source
The study sponsor did not play a role in the study design; data collection, analysis, or interpretation; writing of the report; or decision to submit the paper for publication. The corresponding author had final responsibility for the decision to submit for publication.
RESULTS
The final sample included 540,026 women from 216 sites. Approximately half were younger than 30 years, and most women was Latina and spoke Spanish as their primary language. Almost all women received care from sites that were urban, more than half received care from private clinics and those located in Los Angeles County, and approximately 2 in 5 saw a provider enrolled in Every Woman Counts (see Table 1 ). Although sample sizes varied for each 6-month visit period (see Figure 1) , the distribution of patient and clinic characteristics was consistent across visit periods (data not shown). Figure 2A shows unadjusted rates of 1-year cervical cancer screening by age group. Trends declined for all 3 groups (21-24, The unadjusted rates of 3-year cervical cancer screening by age group also revealed a decrease among all age groups with a significant greater decline in young women (see Figure 2B ). In 2015, 50% of women aged 21 to 24 years were screened compared with 76% of women aged 30 to 64 years. Table 2 presents overall and subpopulation-specific trends in 3-year cervical cancer screening. Between 2011 and 2015, 3-year cervical cancer screening declined overall and within each subgroup. With respect to age, the odds of cervical cancer screening declined for women aged 21 to 24 years by an estimated 11% every 6 months during the observation period (OR = 0.90, 95% CI = 0.89-0.90).
Cervical Cancer Screening Trends
The rate of decline for this youngest group was significantly greater than for those aged 25 to 29 years (ratio of ORs = 1.02, 95% CI = 1.01-1.02) and those aged 30 to 64 years (OR = 1.01, 95% CI = 1.01-1.02). There was no difference in trend, however, between women aged 30 to 64 versus 25 to 29 years (OR = 1.00, 95% CI = 0.99-1.00).
Among women aged 21 to 29 years, declining trends were greater for women who were Latina, Spanish speaking, and who were served by a site located in Los Angeles or not enrolled in Every Woman Counts (all p < .001). For example, the odds of receiving a 3-year cervical cancer screening among Latinas declined by an estimated 10% every 6 months (OR = 0.90, 95% CI = 0.90-0.90), compared with only 6% for non-Latina women (OR = 0.94, 95% = 0.94-0.95), and the difference in these rates of decline was significant (ratio of ORs = 0.95, 95% CI = 0.95-0.96). Trends did not differ significantly by provider type (public vs private sector) or geography (urban vs rural) (eFigure1, http://links.lww.com/LGT/A83).
Chlamydia Screening Among Young Women
Unadjusted rates of 3-year cervical cytology screening and annual chlamydia screening among all women aged 21 to 24 years are displayed in Figure 3 . Trends showed a more modest decline for chlamydia screening compared with the large decline for cervical cancer screening. The difference in decline rate between chlamydia and cervical cancer screening is statistically significant ( p < .001). Young women being screened for both chlamydia and cervical cancer declined between 2011 and 2015 (eFigure2, http:// links.lww.com/LGT/A83).
DISCUSSION
Regular cervical cytology tests contributed to the decrease in cervical cancer mortality through early diagnosis of cervical precancers.
1 Healthy People 2020 targets increasing the proportion of women who receive a cervical cancer screening based on most recent guidelines from 84% in 2008 to 93% in 2020. 16 With the change in guidelines from annual to every 3 years, a decrease in annual screening was expected. Disturbingly, our data show a decreasing trend in the percent of women who had even 1 cervical cytology screening within 3 years, which coincided with the change in guidelines from annual to every 3 years. Although this observation is consistent with other studies, 23, 24 the decline was particularly alarming for women in the younger age group. Only 50% of women aged 21 to 24 years seen by a Family PACT provider in early 2015 had cervical cancer testing within the 6-month visit period or 3 years ago compared with 69% of women aged 25 to 29 years and three quarters of women aged 30 to 64 years. Moreover, all age groups were well below the Healthy People 2020 target. Of note, during 2011-2012, when annual screening was the recommended guideline, three quarters of young women had cervical cancer testing within the 6-month visit period or 1 year ago.
In our analysis, the decline in recommended cervical cytology screening was significantly stronger among Latina women compared with non-Latina women. Nationwide, the percentage of women screened in 2015 was lowest among Latinas at 76% compared with 80% among non-Latina whites and 83% among non-Hispanic blacks.
14 Racial/ethnic health disparities in cervical cancer incidence and mortality could widen, if adoption of new screening guidelines leads to a differential decrease in screening among Latinas and other minority groups.
Clinic sites that participated in the Every Woman Counts program, a potential alternative payer for cervical cytology tests for uninsured low-income women, had a smaller decline of young women in the Family PACT program who were appropriately tested than sites that were not enrolled. This finding may be attributable to higher awareness among clinicians working at Every Woman Counts sites about the need to screen for cervical cancer. There were no differences by provider type (public clinic vs private solo and group medical practices) or clinic geography (urban vs rural location), although the decrease in cervical cancer screening was more pronounced in Los Angeles County compared with the other 9 California counties. One explanation for the decline in cervical cancer screening may be the reduced use of pelvic examinations during family planning visits, which had allowed clinicians to offer cytology testing without the need to take any additional steps. The American College of Obstetrics and Gynecology advised in 2015 that there is no safety or medical benefit in requiring pelvic examinations or cervical cytology tests when dispensing hormonal contraception. 25 Currently, guidelines for chlamydia screening include self-obtained vaginal swabs or urine tests, 26 which discourages pelvic examinations. In our analysis, guideline-specific chlamydia screening had little change, showing that reproductive health care visits were not on the decline in these clinics. It is probable that most of these young women never had a pelvic examination as adolescents and, when offered as a young adult, declined or deferred their examination because of perceived discomfort. We also do not know how many women in this sample received the HPV vaccine and whether they erroneously assumed that the vaccine protected them from cervical cancer screening. Interestingly, a recent study in Canada reported a decline in chlamydia testing that paralleled the introduction of revised cervical cancer guidelines, 27 although an analysis of aggregate data among Title X clinics did not found a decrease in chlamydia testing corresponding to decreased cervical cancer screening. 28 It seems that greater effort toward educating young women regarding cervical cancer is needed. In addition, quality improvement activities within clinics should target missed opportunities for cervical cancer screening during reproductive health visits and adherence with recommended screening and management. 29 For women of all ages, remembering the new screening interval of every 3 years is challenging as compared with annually where the testing date could be pegged to a life event such as birthday, holiday, or anniversary. Equally, it may be difficult for providers to adhere to clinical guidelines that differ by client age unless prompted by a clinic protocol. An analysis of chlamydia screening in the Family PACT program found that providers did not consistently adhere to age-specific guidelines that required annual testing of women younger than 25 years and only risk-specific screening of women 25 years and older. 30, 31 Medical record systems that provide reminders of upcoming screening tests to clinicians or patients could facilitate adherence to triennial screening guidelines. This study of Family PACT providers included a diverse group of public clinics and private group offices with widely varying practice management systems that show the challenges of successfully implementing new clinical guidelines.
The strength of this study is the use of claims data, which avoids recall or social desirability bias observed in surveys. However, claims data do not capture screening tests for which claims were unpaid or never submitted or tests that were received outside Family PACT. Thus, our results may have underestimated cervical cancer screening, albeit not differentially between periods. In addition, variables that may vary across age groups and influence patients' desire for more frequent cervical cytology tests such as having a previous positive cervical cytology result or a family member with cancer could not be assessed in this analysis.
Clinical screening guidelines that seek to avoid unnecessary cervical cytology testing may impact recommended public health screening frequency, hampering the ability of early detection of cancer. Furthermore, the decrease of pelvic examinations during family planning visits may have inadvertently influenced the observed decline in adherence to cervical cancer screening by both patients and providers. Cervical cancer screening programs need to target young adult women.
